ReviewAnnals of surgical oncology2026
Complete Resection of Simultaneous Hepatic and Pulmonary Metastases from Colorectal Cancer in the Era of Modern Systemic and Surgical Therapies: A Systematic Review and Meta-Analysis.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData suggest promising outcomes with resection of simultaneous hepato-pulmonary metastases (HPM) from metastatic colorectal cancer (mCRC). However, there is no consensus regarding the effectiveness of this approach. Therefore, we aimed to evaluate the feasibility and clinical benefit of metastasectomy of simultaneous HPM from mCRC.
methodsA systematic review and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies from PubMed and Embase up to October 1, 2025. Outcomes were reported as proportions and as hazard ratios (HRs) with 95% confidence intervals (CIs).
resultsIn total, 11 studies, encompassing 507 patients with HPM who underwent complete resection, were included. The 5-year overall survival (OS) rate after metastasectomy was 53.61% (95% CI 41.44-65.79), whereas the 3-year OS rate was 70.9% (95% CI 61.73-80.06). The 5-, 3-, and 1-year disease-free survival rates were 14.73%, 19.48%, and 55.31%, respectively. Complete resection was achieved in 45.65% of patients with initial curative intent, with disease progression accounting for 93.18% of treatment failures. Complete metastasectomy was associated with improved OS compared with isolated liver metastasectomy with systemic treatment of pulmonary metastases (HR 0.30; 95% CI 0.19-0.45, p<0.001), whereas isolated liver resection also improved OS compared with systemic treatment alone (HR 0.37; 95% CI 0.27-0.51, p<0.001).
conclusionIn the era of modern therapies, complete resection of HPM from mCRC is associated with a substantial survival benefit and should be considered a primary treatment goal in selected patients. However, less than half of patients with initial curative intent complete the planned treatment. Isolated liver metastasectomy may still confer a survival benefit compared with systemic treatment alone.
Indexed as
Identifiers
42632879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.